Literature DB >> 3501632

The application of hybridoma technology to the study of bovine immunoglobulins.

R A Goldsby1, S Srikumaran, A Arulanandam, B Hague, F A Ponce de Leon, M Sevoian, A J Guidry.   

Abstract

Studies are described in which hybridoma technology is used to produce a variety of reagents for the characterization and manipulation of the bovine humoral immune system. Selected members of a set of murine monoclonal antibodies (MAb) specific for each of four major isotypes of bovine Ig constant regions, one specific for anti-bovine Ig constant regions as well as one specific for anti-bovine light chains are discussed. Interspecific fusion of bovine lymphocytes with the established mouse cell line, SP2/0 was used to produce a collection of stable hybridomas among which were found secretors of bovine IgG1, IgG2, IgM, IgA and bovine light chain. Interspecific fusion of SP2/0 with lymphocytes from a multiparous Holstein four days post immunization with Streptococcus agalactiae yielded MAb with specificity for the immunizing antigen. One of these hybridomas, LHRB 19.17, which displayed a particularly stable secretory phenotype, was used as an immunogen for the production of a library of murine monoclonal anti-idiotype antibodies. Competitive antigen binding analysis showed that 15 of the 24 anti-LHRB 19.17 idiotype antibodies isolated blocked the binding of the idiotype to its nominal antigen and so were candidates for evaluation as antigen mimics. Some of the ways in which monoclonal anti-idiotypes in particular, and monoclonal in general, might be of use in problems of animal disease are discussed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3501632      PMCID: PMC7126093          DOI: 10.1016/0165-2427(87)90124-3

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  20 in total

1.  Induction of neutralizing antibody in mice against poliovirus type II with monoclonal anti-idiotypic antibody.

Authors:  F G Uytdehaag; A D Osterhaus
Journal:  J Immunol       Date:  1985-02       Impact factor: 5.422

2.  Idiotype suppression. I. Influence of the dose and of the effector functions of anti-idiotypic antibody on the production of an idiotype.

Authors:  K Eichmann
Journal:  Eur J Immunol       Date:  1974-04       Impact factor: 5.532

Review 3.  Bovine immunoglobulins: an augmented review.

Authors:  J E Butler
Journal:  Vet Immunol Immunopathol       Date:  1983-03       Impact factor: 2.046

4.  Monoclonal idiotope vaccine against Streptococcus pneumoniae infection.

Authors:  M K McNamara; R E Ward; H Kohler
Journal:  Science       Date:  1984-12-14       Impact factor: 47.728

5.  Passive protection of mice and sheep against bluetongue virus by a neutralizing monoclonal antibody.

Authors:  G J Letchworth; J A Appleton
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.441

6.  Human monoclonal antibody against Forssman antigen.

Authors:  R Nowinski; C Berglund; J Lane; M Lostrom; I Bernstein; W Young; S I Hakomori; L Hill; M Cooney
Journal:  Science       Date:  1980-10-31       Impact factor: 47.728

7.  Protection of calves against fatal enteric colibacillosis by orally administered Escherichia coli K99-specific monoclonal antibody.

Authors:  D M Sherman; S D Acres; P L Sadowski; J A Springer; B Bray; T J Raybould; C C Muscoplat
Journal:  Infect Immun       Date:  1983-11       Impact factor: 3.441

8.  Immunization of mice against African trypanosomiasis using anti-idiotypic antibodies.

Authors:  D L Sacks; K M Esser; A Sher
Journal:  J Exp Med       Date:  1982-04-01       Impact factor: 14.307

9.  Syngeneic monoclonal antiidiotype can induce cellular immunity to reovirus.

Authors:  A H Sharpe; G N Gaulton; K K McDade; B N Fields; M I Greene
Journal:  J Exp Med       Date:  1984-10-01       Impact factor: 14.307

10.  Suppression of idiotypic specificities in adult mice by administration of antiidiotypic antibody.

Authors:  D A Hart; A L Wang; L L Pawlak; A Nisonoff
Journal:  J Exp Med       Date:  1972-06-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.